From Medscape comes an informative article about the growing problem of NAFLD & NASH. The article presents the troubling projections in the growth of non-alcoholic liver diseases in the USA.
The current worldwide prevalence of NAFLD is approaching 25%. The prevalence of NAFLD in the United States is increasing, owing to a rising incidence of obesity and type 2 diabetes mellitus.[8,9] Current US projections indicate a 21% increase in NAFLD numbers, leading to a 33.5% overall prevalence by 2030. Coupled with a 63% increase in patients with nonalcoholic steatohepatitis (NASH), there will be a 168% increase in the number of patients with decompensated end-stage liver disease, and a 137% increase in the numbers of patients developing HCC from NAFLD. The growing numbers of NAFLD patients with hepatic fibrosis indicate that end-stage liver disease from NAFLD will probably become the most common reason for liver transplantation in the United States.
The rest of the article talks about and summarizes all of the useful information available, from lean NASH to treatment options, and includes updated guidance from AASLD (American Association for the Study of Liver Diseases).
Check out the entire article.